May 18, 2016

Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment

Download this presentation to learn more about the challenges and the importance of neutralizing antibodies assays and immunogenicity strategy in drug development to assess and mitigate risk. Immunogenicity testing and immunoassays can be a crucial component of your product's development and success. Q2 Solutions services can meet your immunogenicity and immunoassay needs, from method development and validation, through sample analysis and customized reporting. Our scientists have extensive experience developing and validating variety of assays that support drug development including ELISA, Electrochemiluminescence (ECL), and cell-based immunoassays. At Q2 Solutions, we can develop and validate custom-designed assays as well as ensure the transfer of existing bioanalytical methods.

Paul W. Rhyne, Ph.D.

Related Services:
Immunogenicity Testing in Biologics R&D: Whats your strategy?

Bioanalytical & ADME Laboratory Services

Accelerate and enhance your discovery, preclinical and clinical programs

Custom-Pooled Human Hepatocytes for Clearance Prediction of Aldehyde Oxidase Substrates

Activity and scaling approaches for three separate custom pools of cryopreserved human hepatocytes

Read More